Journal article

Immunomodulatory Effects of Histone Deacetylase Inhibitors

PV Licciardi, K Ververis, ML Tang, A El-Osta, TC Karagiannis



Histone deacetylase inhibitors (HDACi) have emerged as a new generation of anticancer therapeutics. The classical broad-spectrum HDACi typically alter the cell cycle distribution and induce cell death, apoptosis and differentiation in malignant and transformed cells. This provides the basis for the clinical potential of HDACi in cancer therapy. Currently two compounds, suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza™) and depsipeptide (Romidepsin, Istodax™) have been approved for by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma. Apart from clinical application in oncology, HDACi have also been investigated as potential therapeutics f..

View full abstract


Funding Acknowledgements

The support of the Australian Institute of Nuclear Science and Engineering is acknowledged. TCK was the recipient of AINSE awards. The authors acknowledge JDRF Fellowship support. Epigenomic Medicine and Human Epigenetics Labs are supported by the National Health and Medical Research Council (NHMRC) of Australia. PVL is supported by a Training Fellowship provided by the NHMRC and the Allergy and Immune Disorders Laboratories at MCRI have received funding from NHMRC and MCRI. KV is supported by a Baker IDI post-graduate scholarship. Supported in part by the Victorian Government's Operational Infrastructure Support Program. The authors would like to acknowledge the use of the facilities provided by Monash Micro Imaging @ AMREP and particularly, the expert assistance from Drs Stephen Cody and Iska Carmichael.